mTOR signaling in the neuropathophysiology of depression: current evidence

Gislaine Z Réus1
João Quevedo1,2
Ana Lúcia S Rodrigues3
1Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, Santa Catarina, Brazil; 2Center for Translational Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, TX, USA; 3Laboratory of Neurobiology of Depression, Department of Biochemistry, Center of Biological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil

Abstract: Despite significant progress in major depressive disorder (MDD) research over the past decades, the mechanisms underlying its pathophysiology and treatment remain to be established. The complexity and heterogeneity of MDD involves multiple causes, such as inflammation, genetic, and environmental factors that could be related to poor effectiveness, variability of response to antidepressants drugs, delay in clinical response, and side effects. Ketamine, an N-methyl-D-aspartate receptor antagonist, has been proposed as a revolutionary antidepressant that acts rapidly and is effective for treatment-resistant MDD. Ketamine stimulates mammalian target of rapamycin (mTOR), which is involved in transcription, survival, and cell proliferation. mTOR is an emerging signaling pathway of interest in MDD pathophysiology and treatment. Thus, this review describes the role of mTOR in the pathophysiology of MDD as well as highlights therapeutic targets that modulate mTOR signaling.

Keywords: mTOR, antidepressant, major depressive disorder

Introduction

Major depressive disorder (MDD) is a highly prevalent and burdensome psychiatric disorder characterized by several symptoms, including low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities (anhedonia).1,2 In addition to these impairments, this disorder is also associated with a high suicide risk in affected patients.3 The World Health Organization ranks MDD as the fourth leading cause of disability worldwide, and it is estimated that MDD will be the second leading cause of burden of disease in 2030.4

Although several studies have been conducted in an attempt to understand the neurobiological basis of MDD, there is not a complete understanding of the mechanisms that account for the depressive symptoms. However, there is a consensus that MDD is a multicausal disorder whose etiology includes genetical, environmental, and neurobiological factors. One of the main environmental factors associated with MDD is stress. Stressful events during life are highly correlated with the onset and progression of MDD.1,2

The initial hypothesis regarding the neurobiology of MDD was the monoaminergic hypothesis that correlates a reduction in the synaptic levels of monoamines (noradrenaline, serotonin, and dopamine) with depressive symptoms. However, this hypothesis does not explain the fact that remission of the symptoms only occurs after several weeks of treatment with conventional antidepressants (selective serotonin reuptake inhibitors, tricyclics, and atypicals), whereas the enhancement in monoamine levels is observed immediately after the administration of these agents.1,5-6 This lag in the
symptom resolution of conventional antidepressants has led to the assumption that neuroplastic alterations dependent on signaling pathways and modulation of target genes account for the slow therapeutic effects of antidepressants. Preclinical and clinical studies have reported that remission of depressive symptoms depends on the increase in brain-derived neurotrophic factor (BDNF), predominantly in the hippocampus and prefrontal cortex, and hippocampal neurogenesis elicited by antidepressant treatments. This is particularly important considering that MDD is associated with atrophy and loss of neurons and glia, leading to decreased size and function of the prefrontal cortex and hippocampus.

The glutamatergic system has received particular attention as a target for the development of antidepressant agents with better pharmacological profiles than currently used conventional antidepressants. The first preclinical study that showed the antidepressant-like effects of N-methyl-D-aspartate (NMDA) receptor antagonists (AP7 and MK-801) was published in 1990 by Trullas and Skolnick. A review by Skolnick proposed that NMDA receptor antagonists would be antidepressants for the new millennium. This result was bolstered by several preclinical, and clinical studies that have shown that ketamine, an NMDA receptor antagonist, exhibits fast and sustained antidepressant effects. Ketamine has been shown to be effective in patients who were resistant to two or more classes of standard antidepressants.

The fast-acting clinical effect of ketamine has led to a greater interest in the molecular mechanism underlying its antidepressant action. The NMDA receptor antagonism on gamma-aminobutyric acid (GABA)-ergic interneurons with the consequent increase on glutamate levels, followed by the activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and voltage-dependent calcium channels are fundamental steps that lead to an increase in BDNF release in the prefrontal cortex and hippocampus. As a consequence of these events, activation of mammalian target of rapamycin (mTOR) seems to be another fundamental step that accounts for the antidepressant effect of ketamine, since it stimulates the expression of synaptic proteins that are thought to be associated with synaptogenesis and its rapid antidepressant response. Considering these findings, mTOR activation stands out as a key target for antidepressant responses. Therefore, this review presents the main preclinical and clinical evidence that supports this assumption.

The role of mTOR in the central nervous system

mTOR, a 289 kDa evolutionarily conserved serine/threonine protein kinase, may be activated by phosphorylation in response to growth factors (such as BDNF), mitogens, and stress. It has been recognized to have an essential role in the regulation of protein synthesis, energy metabolism, lipid metabolism, cell growth and size, autophagy, and lysosome biogenesis. In the brain, mTOR is also involved in axonal sprouting, axonal regeneration and myelination, ionic and receptor channel expression, dendritic spine growth, and astrocyte migration and proliferation. mTOR-regulated processes in the brain influence neuronal excitability, neuronal survival, synaptic and behavioral plasticity, cognition, feeding, and control of circadian rhythm.

The function of mTOR signaling is mediated via two mTOR complexes: mTORC1 and mTORC2. mTOR function is influenced by the activities of several receptors, including NMDA, AMPA, tropomysin receptor kinase B (TrkB), dopaminergic, and metabotropic glutamate receptors (mGluRs). NMDA receptor activation is associated with phosphorylation of intracellular pathways, including protein kinase B (Akt) and protein phosphatases that in turn can activate glycogen synthase kinase-3 (GSK-3). GSK-3 has been reported to suppress mTOR signaling in the hippocampus. In addition, the inhibition of GSK-3 is required for the antidepressant effects of ketamine.

Activated mTOR phosphorylates the 70 kDa ribosomal protein S6 kinase 1 (p70S6K) and also phosphorylates and inactivates the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) reducing its affinity for the eukaryotic initiation factor 4E (eIF4E), thus releasing eIF4E to facilitate translation initiation. mTORC1 has been shown to be associated with protein translation. It is formed by a catalytic subunit, mTOR, and Raptor, which is an mTOR-binding protein that also binds to p70S6K and 4E-BP1. Moreover,
mTORC1 complex activity is stimulated by oxidative stress and inflammation, and by growth factors through both phosphoinositide 3 kinase (PI3K)-Akt and Ras-extracellular signal-regulated kinase (ERK)-mediated pathways. In contrast, mTORC2 regulates the development of the cytoskeleton and also controls cell survival.

mTORC1 is sensitive to inhibition by the macrolide antibiotic rapamycin. Conversely, mTORC2 is relatively resistant to rapamycin, and prolonged treatment is required for rapamycin to inhibit the activity of mTORC2. Rapamycin inhibits the P70S6K and 4E-BP1 phosphorylation, thus reducing transcription and translation of protein mediated by mTOR signaling. It prevents mTOR from further phosphorylation of P70S6K, 4E-BP1, thus indirectly decreasing the proteins involved in transcription and translation of this signaling. A body of evidence has found that rapamycin exhibits anti-proliferation and anti-migration properties in many types of cells.

mTOR is also known to exert an important role in the development of the brain. This effect appears to be mediated by BDNF and includes learning and memory formation in the hippocampus and synaptogenesis in the prefrontal cortex. The formation of learning and memory mediated by mTORC1 is promoted via protein synthesis-dependent strengthening of synapses. The role of mTOR in memory is supported by the fact that hyperactivation of PI3K/Akt/mTOR signaling was shown in postmortem samples of the inferior parietal lobule in patients with Alzheimer’s disease (AD).

Excessive mTOR activity is involved in maladaptive memory and learning and with abuse disorders. For example, alcohol administration in mice increased mTOR activation in the nucleus accumbens, a brain area associated with addiction and reward. On the other hand, decreased mTOR and associated cascades are also involved with learning and memory impairment. In a preclinical study, memory, learning, and social behavior impairment in mice deficient of 4E-BP1 was reported. Changes in nutrition are also associated with altered mTOR activity. In some parts of hypothalamus in which there are higher ambient levels of phosphorylated S6K1 (a marker for mTORC1 activity), this activity decreases during fasting conditions. For instance, Su et al demonstrated that a long-term protein-rich diet restored learning and memory impairment in rats via upregulation of mTOR/p70S6K signaling.

Since mTOR is involved in memory processes and neuronal plasticity, it stands to reason that several studies have correlated mTOR activity and its associated signaling cascades with the pathophysiology of some nervous system disorders such as Parkinson’s disease, AD, Huntington’s disease, bipolar disorder, and MDD. Thus, targeting the mTOR pathway could be very important in understand the pathophysiology of these diseases and for the development of new therapeutic strategies.

Preclinical evidence supporting the role of mTOR signaling in the neuropathophysiology of MDD

The activation of several intracellular signaling pathways plays a role in synaptic neurotransmission and plasticity, mechanisms critical to cell survival, and mood regulation. In the last few years, special attention has been given to the role of mTOR signaling in mood modulation. Several studies have reported decreased brain mTOR activation in animal models of depression (Figure 1). Regarding these models, one of the most studied is chronic unpredictable stress (CUS), which mimics several behavioral and neurochemical alterations that occur in depressive individuals. In this model, rodents are exposed to long-term, mild, but unpredictable stressors and develop a state of impaired reward salience that mimics the anhedonia observed in many depressive patients.

Mice and rats exposed to CUS exhibit depressive-like behaviors associated with a reduction in phosphorylation levels of mTOR and its downstream signaling components, such as phosphor-p70S6K, in the prefrontal cortex, hippocampus, and amygdala. Also, the genetic deletion of mTOR in mice recapitulates depressive-like behaviors induced by CUS. The successive administration of corticosterone to mouse cortical neuron cultures, a model that resembles the effects of stress, was also shown to reduce the phosphorylation levels of mTOR. However, rats submitted to 10-day restraint stress presented an overexpression of mTOR in the hippocampus. In the model of depression induced by neonatal clomipramine administration, the phosphorylation of p70S6 kinase, one of the mTOR downstream effectors, was significantly decreased in the hippocampus, hypothalamus, and frontal cortex of clomipramine-treated rats, suggesting that reduction in mTOR activation is associated with depression-related situations.

Regarding the role of mTOR signaling in the behavioral response of antidepressant drugs, an elegant study that has provided insight into the role of this protein in the neuropathophysiology of MDD was published by Li et al. In this study, a single dose of ketamine was able to activate the mTOR signaling pathway, resulting in increased prefrontal cortex synaptic protein expression within 2 hours and increased dendritic spine density and synaptic activity.
within 24 hours. The synaptic actions of ketamine allow rapid recovery from the insults produced by exposure to repeated stress that cause neuronal atrophy and loss of synaptic connections. Ketamine’s effects on behavior and synaptogenesis in the prefrontal cortex seem to be mediated by activation of mTOR signaling, since rapamycin administration was able to prevent ketamine’s effects.20,28 These results are particularly important in elucidating ketamine’s therapeutic mechanism of action and fast-acting antidepressant properties.

It was also demonstrated that the acute administration of ketamine increased BDNF levels and p-mTOR in the hippocampus of rats and produced an antidepressant effect in the forced swimming test (FST).58 More recently, a study by Zhou et al41 also showed the antidepressant-like effect of ketamine during the FST associated with an increase in hippocampal and prefrontal cortical mTOR phosphorylation and enhanced BDNF levels. These effects were attenuated or abolished (depending on the dose) by the AMPA receptor antagonist NBQX. On the other hand, the ability of ketamine to increase mTOR phosphorylation and BDNF levels in both brain structures was potentiated by the AMPA receptor agonist CX546. These results indicate that the antidepressant effect of ketamine is associated with upregulation of mTOR and BDNF through AMPA receptor activation as a consequence of BDNF release due to AMPA receptor activation. On the other hand, rapamycin inhibits mTOR activity and blocks antidepressant effects of ketamine and other glutamatergic agents. Activated mTORC1 phosphorylates p70S6K and also phosphorylates and inactivates 4E-BP1, reducing its affinity for eIF4E. Reduced mTOR activity is generally associated with depressive symptoms.

**Figure 1** Potential strategies for the management of MDD targeting mTOR signaling.

**Notes:** Several studies have suggested that the activation of mTOR may elicit antidepressant effects. Ketamine and some glutamatergic agents, including ascorbic acid, creatine, zinc, and guanosine, as well as mGluR5 agonist LY341495, mGlu7 agonist AMN082, the glycine binding site NMDA receptor antagonist 7-CTKA, and NMDAR glycine site functional partial agonist GLYX-13 which present antidepressant properties, are reported to cause mTOR activation. Also, 5-HT2C receptor antagonists, mTOR, mammalian target of rapamycin, and physical exercise may cause mTOR activation.

**Abbreviations:** MDD, major depressive disorder; mTOR, mammalian target of rapamycin; NMDA, N-methyl-D-aspartate; mGluR, metabotropic glutamate receptor; NMDAR, N-methyl-D-aspartate receptor; 5-HT2C, 5-hydroxytryptamine 2C.

**Figure 2** Role of mTOR signaling pathway in the pathophysiology of MDD.

**Notes:** mTOR function is influenced by the activities of several receptors, including NMDA, AMPA, and TrkB. Exposure to chronic stress or corticosterone can reduce mTOR activation, whereas the activation of GSK-3 is associated with mTOR inhibition. Ketamine and other compounds cause mTOR activation. Particularly, ketamine activates mTOR through the activation of TrkB receptors as a consequence of BDNF release due to AMPA receptor activation. On the other hand, rapamycin inhibits mTOR activity and blocks antidepressant effects of ketamine and other glutamatergic agents. Activated mTORC1 phosphorylates p70S6K and also phosphorylates and inactivates 4E-BP1, reducing its affinity for eIF4E. Reduced mTOR activity is generally associated with depressive symptoms.

**Abbreviations:** AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BDNF, brain-derived neurotrophic factor; eIF4E, eukaryotic initiation factor 4E; GSK-3, glycogen synthase kinase-3; NMDA, N-methyl-D-aspartate receptor; mTOR, mammalian target of rapamycin; 70-kDa ribosomal protein S6 kinase 1; TrkB, tropomyosin receptor kinase B; ERK, Ras-extracellular signal-regulated kinase; Akt, protein kinase B.
neurons, an effect blocked by inhibition of AMPA receptors.\(^{99}\) In addition, this study showed that BDNF antibody administered into the prefrontal cortex blocked the antidepressant effect of ketamine in the FST. L-type calcium channel antagonists also abolished the behavioral effects of ketamine in this test, suggesting that the activation of L-type calcium channels that occurs as a consequence of AMPA receptor activation is associated with the antidepressant effect of ketamine. Also, ketamine-mediated blockade of NMDA receptors at rest causes effects compatible with mTOR activation, namely the deactivation of eukaryotic elongation factor 2 (eEF2) kinase, leading to reduced eEF2 phosphorylation and the consequent BDNF translation.\(^{60}\)

Considering the relationship between GSK-3 and mTOR,\(^{29,30}\) it is not surprising that inhibition of GSK-3 is required for the rapid antidepressant-like effect of ketamine. A study by Beurel et al\(^{29}\) showed that treatment of mice with ketamine rapidly increases phosphorylation of both \(\alpha\) and \(\beta\) isoforms of GSK-3, causing an inhibition of GSK-3 activity and that mice carrying a mutant form of GSK-3 that prevents its phosphorylation are resistant to the antidepressant-like effect of ketamine in learned helplessness.

Another antidepressant strategy in preclinical studies has been the association of subeffective doses of ketamine and other compounds. For example, tramadol enhanced the ketamine-induced antidepressant effects and upregulated the expression of mTOR in the hippocampus and prefrontal cortex of rats.\(^{61}\) The effects of ketamine on the FST and on synaptogenesis in the prefrontal cortex were potentiated by the GSK-3 inhibitors lithium and SB 216763.\(^{30}\) A study by Chiu et al\(^{62}\) also reported that the combination of subeffective doses of lithium and ketamine caused an antidepressant-like effect in the FST associated with activation of mTOR signaling pathway in prefrontal cortex. Finally, the combined administration of subeffective doses of AMPA and ketamine caused antidepressant effect in the FST and sucrose preference test associated with increases in hippocampal BDNF, synapsin levels, and mTOR phosphorylation in rats.\(^{63}\)

A number of additional compounds have also been reported to possess antidepressant properties primarily by modulating glutamatergic neurotransmission and may activate mTOR in prefrontal cortex and/or hippocampus (Figure 1). Ascorbic acid, a putative neuromodulator with antioxidant properties that possesses neuroprotective effects against glutamate-induced neurotoxicity,\(^{64,65}\) produced antidepressant-like effects in several behavioral tests\(^{66–68}\) and was reported to afford beneficial effects against depressive symptoms\(^{69}\) and to increase mood in healthy young adults.\(^{70}\) A single administration of ascorbic acid increased the phosphorylation p70S6K, a downstream target to mTOR, and the immunocontent of the synaptic protein PSD-95 in the hippocampus of mice. Of note, this effect occurred just 1 hour after its administration. In addition, rapamycin was able to abolish the antidepressant-like effect of ascorbic acid in the tail suspension test (TST).\(^{71}\) In a mechanism similar to that of ascorbic acid, mTOR signaling was also implicated in the antidepressant-like effect of guanosine in the TST,\(^{72}\) a purine nucleoside that has been shown to modulate glutamatergic neurotransmission.\(^{73}\) More recently, it was demonstrated that creatine, an endogenous ergogenic compound that has shown neuroprotective properties against several agents, including NMDA-induced excitotoxic damage,\(^{74}\) exerts antidepressant-like effect in the TST by a mechanism dependent on NMDA receptor inhibition,\(^{75}\) Akt, Nrf2/HO-1, GPx, and mTOR activation, and GSK-3 inhibition.\(^{76}\) Creatine administered acutely increased the phosphorylation of p70S6K and Akt, proteins downstream, and upstream to mTOR, respectively, suggesting that mTOR activation may account for its antidepressant-like effects. This assumption was reinforced by the finding that rapamycin abolished the antidepressant-like effect of creatine in the TST.\(^{76}\) More recently, it was shown that the activation of mTOR signaling pathway is also implicated in the antidepressant-like effect of zinc, a metal ion that inhibits NMDA receptors.\(^{77}\)

Besides the putative ability of the glutamatergic modulators ascorbic acid, guanosine, creatine, and zinc to produce antidepressant effects by modulating mTOR signaling, erythropoietin, scopolamine, and other glutamatergic agents seem to act via this mechanism.

Erythropoietin and the muscarinic receptor antagonist scopolamine were reported to produce an antidepressant-like effects in the FST, and rapamycin was able to abolish these effects.\(^{78,79}\) Erythropoietin also promoted adult hippocampal neurogenesis, an effect exhibited by effective antidepressants.\(^{78}\) Besides mTOR signaling, the antidepressant effects of scopolamine are associated with increased glutamate transmission, and synaptogenesis, similar to ketamine.\(^{79}\)

A single dose of the mGluR\(_{2/3}\) antagonist LY341495 rapidly (1 hour) activated the mTOR pathway (mTOR, p70S6K, 4E-BP1) and subsequently (24 hours later) increased levels of synaptic proteins (PSD-95, GluR1, and synapsin I) in a manner similar to ketamine. Reinforcing the critical role of mTOR for the antidepressant-like effect of LY341495, its anti-immobility effect in the rat FST was abolished by rapamycin.\(^{80}\) However, a previous study showed that rapamycin blocked the sustained, but not the acute, antidepressant-like effects of mGlu2/3 receptor antagonists MGS0039 and
LY341495, suggesting that the activation of mTOR signaling may contribute to the sustained antidepressant-like effects of mGlu2/3 receptor antagonists.81

A recent study showed that the mGlu7 agonist AMN082 administered 1 hour before the FST increased the levels of p-mTOR and p-p70S6K, and rapamycin reversed its antidepressant-like effect in the FST in rats. This study showed that synapsin I and GluR1 levels were increased in the prefrontal cortex, further indication that AMN082 acts by activating mTOR signaling.82

Reinforcing the notion that mTOR is implicated in the mechanism underlying the fast-acting antidepressants, a single administration of the glycine binding site NMDA receptor antagonist 7-CTKA produced rapid antidepressant-like effects associated with increased p-GSK3β (causing inhibition of this enzyme), enhanced mTOR function, and increased postsynaptic protein levels in the medial prefrontal cortex of rats.52 It was also recently shown that GLYX-13, an NMDA receptor (NMDAR) glycine site functional partial agonist, was able to acutely reverse chronic mild stress-induced depressive-like behavior and reduction in Akt and mTOR phosphorylation in the hippocampus of mice. In addition, rapamycin blocked the antidepressant-like effect of GLYX-13.83

Clinical evidence supporting the role of mTOR signaling in the neuropathophysiology of MDD

A study by Jernigan et al84 investigated the expression of mTOR and its downstream signaling targets: p70S6K, elf4E, elf4E phosphorylated at serine 209 (p-elf4E-Ser209), elf4B, and elf4B phosphorylated at serine 504 (p-elf4B-Ser504) in the prefrontal cortex of 12 depressed individuals and 12 psychiatrically healthy controls. This study showed a reduction in mTOR, p70S6K, elf4B, and p-elf4B protein expression in MDD subjects when compared with controls, pointing to a deficit in mTOR-dependent signaling leading to impairment in its downstream targets that control translation of synaptic proteins. A similar result regarding mTOR was shown in blood samples taken from bipolar patients during depressive episodes; mTOR mRNA and Akt mRNA expression was reduced in comparison with healthy controls, alterations that correspond to that observed in brain samples.85 Additionally, the treatment of three depressive patients with a subanesthetic dose of ketamine afforded a rapid amelioration of depression symptoms associated with acute increases in the expression of plasma mTOR and GSK-3, as well as eEF2 phosphorylation.86

Of note, levels of the NR2A and NR2B subunits of NMDA receptors and the postsynaptic protein PSD95, a target downstream to mTOR, were found to be reduced in postmortem samples of prefrontal cortex Brodmann’s area 10 (BA10) in depressed individuals when compared with psychiatrically healthy controls.87 However, increased levels of NR2A and PSD-95 were reported in amygdala samples of depressed individuals.88 The alterations found in the prefrontal cortex BA10 region may be related to the depressive symptoms, since BA10 is not only associated with executive functions such as planning and integrative information processing, but also in reward and reinforcement processing.89,90 Therefore, this area may be involved in mood regulation, considering that depressive patients may exhibit impaired reward responsiveness, characterizing a reduced hedonic behavior.91

Postmortem studies have also showed increased expression of mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) in the dentate gyrus and CA1 region of the hippocampus of depressive subjects when compared with matched controls.92 This study also demonstrated significant downregulation of mitogen-activated protein kinase (MAPK) kinase 2 (MEK2) in the CA1 region of subjects with depression and a decrease in ERK2, a MAP kinase directly regulated by MKP-1, in the dentate gyrus. This corresponds with a previous postmortem study that showed reduced activation and expression of ERK1/2 MAP kinase in the postmortem prefrontal cortex and hippocampus of depressed suicide subjects.93 Considering that MKP-1 is a key negative regulator of the MAPK cascade4 that is also upstream to mTOR, it is possible that it can impair mTOR signaling in the prefrontal cortex and hippocampus of depressive individuals.

Altogether, the clinical studies point to a possible association between marked deficits in synaptic proteins and dysregulation of mTOR signaling, mainly in the prefrontal cortex of depressive individuals. The role of mTOR signaling in other brain regions, particularly the hippocampus and amygdala, in the neuropathophysiology of depression remains to be established.

Limitations associated with therapeutic targeting mTOR

Several studies indicate that inhibition of mTORC1 can be beneficial for some pathological conditions such as epilepsy, cognitive impairment, cancer therapy and as an immunosuppressant to prevent graft rejection in transplant recipients, whereas stimulation of mTORC1 can be beneficial for depression or axonal growth and regeneration.23 The broad therapeutic roles of targeting mTOR are a result of the essential role mTOR signaling plays in several biological
functions, as previously mentioned in this review. Since depressive symptoms are often present in several pathological conditions associated with brain mTOR stimulation (such as epilepsy, cancer, and AD) targeting mTOR for the treatment of depression has some limitations. It should be noted that a significant percentage of depressive patients would likely not benefit from pharmacological strategies targeting brain mTOR activation. We should also state that glutamatergic agents that activate mTOR, such as ketamine, may not be safe for chronic treatment. Regarding these limitations, modulators of mTOR devoid of psychomimetic effects are needed. However, even with safer agents, the effects of long-term modulation of mTOR have yet to be investigated.

It is also important to note that there are some controversial effects regarding the possible role of mTOR in depression. Chronic treatment with rapamycin for 17 weeks in WAG/Rij (Wistar Albino Glaxo/Rij) rats, a genetic model of absence epilepsy, epileptogenesis, and mild-depression comorbidity, caused antiepileptogenic effects accompanied by prodepressant effects, but subchronic treatment (7 days) with rapamycin had no effect on forced swim behavior in healthy Wistar rats and caused antidepressant-like effects in the WAG/Rij rats. Also, the antidepressant-like effects of subchronic administration of rapamycin were shown in two predictive models of antidepressant activity, the FST and TST in mice and rats, although the authors proposed that this effect may be dependent on other intracellular interactions besides mTOR inhibition. Interestingly, sleep deprivation, a non-pharmacological antidepressant treatment that rapidly alleviates depressive symptoms in ~60% of depressed patients, was reported to reduce levels of total and phosphorylated mTOR in the mouse hippocampus. These results suggest that, at least under some conditions, mTOR inhibition may be associated with antidepressant responses. These data indicate that the role of mTOR signaling in mood regulation is complex and requires further studies to investigate the mechanisms underlying these effects.

A recent in vitro study showed that the antidepressants escitalopram, paroxetine, and tranylcypromine, similar to ketamine, significantly increased levels of p-mTOR and its downstream regulators (p-4E-BP1 and p-p70S6K), and increased hippocampal dendritic outgrowth and synaptic proteins levels, whereas fluoxetine, sertraline, and imipramine caused no effect on these parameters in rat hippocampal cultures. This result is somewhat in agreement with the finding that imipramine or fluoxetine (as well as electroconvulsive treatment) did not affect mTOR signaling in the prefrontal cortex of rats. These in vitro results suggest that some monoaminergic antidepressants may promote dendritic outgrowth and increase synaptic protein levels through mTOR signaling. However, it remains to be determined whether these antidepressants are able to elicit these effects in vivo. It is possible that these antidepressants do not reach concentrations in vivo that are sufficient to activate mTOR signaling.

Treatment with 5-hydroxytryptamine 2C (5-HT₂C) receptor antagonists was also reported to induce fast-onset antidepressant effects associated with the activation of mTOR and eEF2 in the prefrontal cortex of mice. Of note, subchronic treatment with selective serotonin reuptake inhibitors, which did not induce antidepressant behavioral effects, also activated mTOR and eEF2, indicating that these effects are not sufficient for antidepressant onset.

Finally, a transient activation of mTOR was shown in the hippocampus of rats subjected to forced treadmill exercise (1 day of exercise, but not 2 or 8 weeks of exercise). Considering that exercise is associated with antidepressant effects, this finding deserves further studies to understand the role of mTOR signaling in antidepressant responses.

The exact mechanism by mTOR signaling pathway may modulate mood is unknown. The decreased mTOR signaling may impair synaptic plasticity, cellular resilience, and energy production that may contribute to the development of MDD.

Conclusion
In this review, we present basic research data combined with clinical studies indicating that mTOR signaling plays a crucial role in the neuropathophysiology of depression (Figure 2). Overall, it seems that depression is associated with a reduced activity of this enzyme, whereas antidepressant treatments, mainly glutamatergic agents such as ketamine, have been shown to cause an activation of this protein through its phosphorylation, especially in the prefrontal cortex and hippocampus. It remains to be established whether antidepressant agents that cause an activation of this enzyme are able to induce a fast-onset therapeutic response. A better understanding on the role of mTOR signaling in different brain regions and its upstream and downstream targets may provide novel insights into the development of therapeutic approaches for the management of MDD.

Acknowledgments
The Center for Translational Psychiatry (USA) is funded by the Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston. Laboratory of Neurosciences (Brazil) is one of the centers of...
the National Institute for Molecular Medicine (INCT-MM). Laboratory of Neurobiology of Depression and Laboratory of Neurosciences (Brazil) are members of the Center of Excellence in Applied Neurosciences of Santa Catarina (NENASC). Work in the authors’ laboratories has been funded by grants from CNPq, CAPES, FAPESC, Instituto Cerebro e Mente, and UNESC, Brazil. JQ and ALSR are CNPq Research Fellows.

Disclosure
The authors report no conflicts of interest in this work.

References


82. Palucha-Poniewiera A, Szewczyk B, Pile A. Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlur5 antagonist MTEP and the mGlur7 agonist AMN082 in the FST in rats. Neuropharmacology. 2014;82:59–68.


